EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

EyePoint Pharmaceuticals (EYPT) shares fell ~70% after DURAVYU failed to meet the primary endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. The company reported favorable secondary results, including a 42% reduction in treatment burden. Levi & Korsinsky is investigating potential securities fraud claims on behalf of EYPT investors who lost money.

EyePoint Pharmaceuticals (EYPT) reported that its phase III study for Duravyu in wet age-related macular degeneration (wet AMD) missed the primary endpoint, causing shares to drop 67%. The study did not show non-inferiority to Regeneron's (REGN) Eylea in the full dataset, but Duravyu met key secondary endpoints, including a 42% reduction in treatment burden. The company plans to present additional data and awaits results from a second phase III study, LUCIA, expected in Q4 2026. EYPT shares have

EyePoint Inc. (EYPT) shares fell again in pre-market after a Phase 3 wet AMD trial setback. RBC Capital downgraded EYPT to Sector Perform from Outperform and cut its price target about 86% to $5, citing Duravyu’s failure to meet the primary endpoint versus aflibercept. RBC and H.C. Wainwright said regulatory and clinical uncertainty could persist; results expected in Q4.

EyePoint (EYPT) reported topline Phase 3 LUGANO results for DURAVYU (vorolanib intravitreal insert) in wet AMD. The trial missed the primary endpoint versus aflibercept in the full dataset, but an ad hoc analysis excluding a small cohort showed non-inferiority (p=0.0096). Secondary results included a 42% treatment-burden reduction (p<0.0001). LUCIA data expected Q4 2026.

EyePoint, Inc. (EYPT) shares fell about 69% after topline results from the LUGANO Phase 3 trial of DURAVYU in wet age-related macular degeneration missed the primary endpoint. The stock traded around $4.585 on Monday versus a prior close of $14.75. An ad hoc analysis excluding a 4% cohort suggested non-inferiority to on-label aflibercept.

EyePoint (EYPT) shares fell about 69% after its Duravyu treatment for wet age-related macular degeneration missed the primary endpoint in a late-stage study, according to the company. Results cited include a 42% reduction in treatment burden and 56% of patients supplement-free by week 56, but the trial did not meet its main goal.